Longevity Fund Bets Big on Forever Health With Moonshot Biotech

Immortal Dragons, a Singapore‑based longevity fund led by 34‑year‑old Boyang Wang, has raised about $40 million to back high‑risk, high‑reward biotech projects aimed at extending healthspan and potentially delaying death. Its portfolio includes Frontier Bio’s 3D organ fabrication, a project to create nonsentient mammals for research, and Unlimited Bio’s gene therapies, plus a neuroscience collaboration with Stanford and advocacy like New Hampshire’s Right to Try law. The effort sits within billionaire‑driven bets on longevity while raising ethical, cost and access questions about making “death optional.”